重组ADAMTS13治疗减轻人镰状细胞病小鼠模型缺氧/复氧诱导的病理改变
在暴露于缺氧/复氧应激的人源化镰状细胞病(SCD)小鼠模型中,给予重组ADAMTS13(rADAMTS13)可剂量依赖性提高血浆ADAMTS13活性、降低VWF活性/抗原比值并减少基线溶血;复氧期恢复显著改善(p < .01)。体外人源系统显示rADAMTS13可抵消血红蛋白对VWF/ADAMTS13轴的抑制活性。
要点
- rADAMTS13在SCD小鼠中剂量依赖性提高血浆ADAMTS13活性并降低VWF活性/抗原比值。
- rADAMTS13在24小时内降低SCD小鼠基线溶血(游离血红蛋白和总胆红素)。
- 缺氧/复氧应激后,rADAMTS13降低VWF活性/抗原比值并显著改善复氧期恢复(p < .01)。
核心结论
- SCD小鼠中相对的ADAMTS13不足可通过rADAMTS13药物治疗得到纠正,并在人SCD小鼠模型中提供一种有效的疾病修饰方法。
研究设计与样本
- 在人源化SCD小鼠模型中经缺氧/复氧应激模拟血管闭塞危象(VOC),进行rADAMTS13体外或体内药物治疗,并开展药代动力学、药效学和行为学分析。
主要发现
- 给予SCD小鼠rADAMTS13后,血浆ADAMTS13活性剂量依赖性升高,VWF活性/抗原比值降低,24小时内基线溶血(游离血红蛋白和总胆红素)减少。
- SCD小鼠给予rADAMTS13后接受缺氧/复氧应激,VWF活性/抗原比值降低,同时复氧期恢复显著改善(p < .01)。
- 在人源体外系统中,rADAMTS13治疗可抵消血红蛋白对VWF/ADAMTS13轴的抑制活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sickle cell disease (SCD) is an inherited red blood cell disorder with a causative substitution in the beta-globin gene that encodes beta-globin in hemoglobin. Furthermore, the ensuing vasculopathy in the microvasculature involves heightened endothelial cell adhesion, inflammation, and coagulopathy, all of which contribute to vaso-occlusive crisis (VOC) and the sequelae of SCD. In particular, dysregulation of the von Willebrand factor (VWF) and a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) axis has been implicated in human SCD pathology. OBJECTIVES: To investigate the beneficial potential of treatment with recombinant ADAMTS13 (rADAMTS13) to alleviate VOC. METHODS: Pharmacologic treatment with rADAMTS13 in vitro or in vivo was performed in a humanized mouse model of SCD that was exposed to hypoxia/reoxygenation stress as a model of VOC. Then, pharmacokinetic, pharmacodynamic, and behavioral analyses were performed. RESULTS: Administration of rADAMTS13 to SCD mice dose-dependently increased plasma ADAMTS13 activity, reduced VWF activity/antigen ratios, and reduced baseline hemolysis (free hemoglobin and total bilirubin) within 24 hours. rADAMTS13 was administered in SCD mice, followed by hypoxia/reoxygenation stress, and reduced VWF activity/antigen ratios in parallel to significantly (p < .01) improved recovery during the reoxygenation phase. Consistent with the results in SCD mice, we demonstrate in a human in vitro system that treatment with rADAMTS13 counteracts the inhibitory activity of hemoglobin on the VWF/ADAMTS13-axis. CONCLUSION: Collectively, our data provide evidence that relative ADAMTS13 insufficiency in SCD mice is corrected by pharmacologic treatment with rADAMTS13 and provides an effective disease-modifying approach in a human SCD mouse model.
引用
- Rossato P, Glantschnig H, Canneva F, et al. Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease. J Thromb Haemost. 2022. PMID: 36700507. doi:10.1016/j.jtha.2022.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。